Semaglutide
GLP-1 agonist. Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus); research-chemical versions are not the approved drug.
Key facts
- Class
- GLP-1 agonist
- Also called
- sema, Ozempic
- Vial sizes sold
- 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg
- Community-reported sizes
- Half-life
- approximately 1 week
- subcutaneous, in people · FDA label (Ozempic)
- FDA status
- Approved (Ozempic, Wegovy, Rybelsus)
- Approved
- WADA
- Not listed
- 2026 Prohibited List
Semaglutide guides
Explained
Evidence at a glance
Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.
| Condition | Human studies | Animal studies | Studies we summarised | Evidence grade |
|---|---|---|---|---|
| Weight loss | 1,978 | 160 | 14 | Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40934115 |
| Diabetes | 1,986 | 139 | 5 | Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 38785209 |
| Energy | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Muscle growth | Not in our ledger | Not in our ledger | 1 | No graded study for this goal |
| Kidney disease | Not in our ledger | Not in our ledger | 2 | Human RCT evidence, 4 of 4Nature medicine 2025, PMID 39455729 |
| Liver health | 305 | 59 | 2 | Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40305708 |
| Depression | Not in our ledger | Not in our ledger | 2 | Human observational evidence, 3 of 4EClinicalMedicine 2024, PMID 39764175 |
| Joint pain | Not in our ledger | Not in our ledger | 1 | Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 39476339 |
| Cognition | Not in our ledger | Not in our ledger | 3 | Human RCT evidence, 4 of 4Lancet 2026, PMID 41865758 |
| Inflammation | 5 | 0 | 2 | Human RCT evidence, 4 of 4American heart journal 2025, PMID 40345413 |
| ADHD | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Heart health | 906 | 38 | 8 | Human RCT evidence, 4 of 4American heart journal 2025, PMID 40345413 |
| Eyes | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Gut health | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
| Women | Not in our ledger | Not in our ledger | 0 | No graded study for this goal |
Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.
Semaglutide in one paragraph
Semaglutide is sold under separate brand names for diabetes and for weight management. The Wegovy label calls it a GLP-1 receptor agonist.[26]
The Ozempic label gives an elimination half-life of approximately 1 week.[14]
Strongest finding and the unresolved question
In STEP 1, mean body-weight change was -14.9% on semaglutide against -2.4% on placebo.[27]
In the SELECT trial of adults with obesity and no diabetes, a primary cardiovascular event occurred in 6.5% on semaglutide against 8.0% on placebo (hazard ratio 0.80).[28]
Body composition is an open question: a systematic review found lean mass made up from almost 0% to 40% of the weight lost across trials.[29]
Observational data on mood disagree, and none of it is randomized. One cohort reported a 195% higher risk of major depression among people on GLP-1 drugs.[30]
A different cohort, in type 2 diabetes, found no higher 12-month risk of adverse neuropsychiatric outcomes than with other diabetes drugs.[10]
Regulatory path
Drugs@FDA lists semaglutide as a prescription product; the cached record shows the tablet form with an original approval date of 20190920.[2]
In the EU the centrally authorised list includes Wegovy with status Authorised.[31]
WADA's S0 catch-all applies only to substances with no government approval, so approved semaglutide is outside it.[1]
Compared with
Common stacks
Semaglutide is often sold pre-mixed or combined with other peptides. A few of these pairs appear together in published studies; each stack page lists what was tested, and the pages below cover the math and what each part has been studied for.
Common questions
Is Semaglutide FDA approved?
Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Products sold as research chemicals are not the approved drug and are not checked by the FDA.
How much water goes in a 10 mg vial?
That choice only changes the concentration. With 2 mL, the vial is 5 mg/mL. The calculator converts any amount to syringe units. It does the math only and does not suggest a dose.
What is semaglutide?
A GLP-1 receptor agonist; the Wegovy label uses that wording.[26]
Is there oral semaglutide?
In a randomized trial of oral semaglutide, mean weight change at 64 weeks was -13.6% against -2.2% on placebo.[6]
What does semaglutide do besides weight loss?
In people with type 2 diabetes and chronic kidney disease, a kidney-outcome trial found a 24% lower risk of a primary-outcome event.[7]
Sources
- 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 2United States: Approved by FDA as Ozempic (2017), Rybelsus (2019) and Wegovy (2021), semaglutide, Novo Nordisk. Ozempic is indicated for type 2 diabetes; Wegovy for weight reduction and cardiovascular risk reduction (see label quotes). Drugs@FDA also lists a tentatively approved generic semaglutide application (Apotex, 7 Apr 2026).U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 3FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 4FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 6Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 7Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
- 8Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial.Nature medicine · 2025PMID 39455729Accessed 2 Oct 2026
- 9Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 1012-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study.EClinicalMedicine · 2024PMID 39764175Accessed 2 Oct 2026
- 11Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.The New England journal of medicine · 2024PMID 39476339Accessed 2 Oct 2026
- 12Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 13Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
- 14These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: semaglutide[ti] AND (STEP OR "once-weekly semaglutide in adults with overweight or obesity" OR "Semaglutide 2.4 mg") AND randomized controlled trial[pt] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: semaglutide[ti] AND (cardiovascular outcomes OR "SELECT" OR "SUSTAIN" OR "PIONEER 6" OR "myocardial infarction") (560 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: semaglutide[ti] AND (kidney OR FLOW OR "steatohepatitis" OR ESSENCE OR "heart failure" OR "knee osteoarthritis" OR Alzheimer) (590 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: semaglutide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR obesity OR cardiovascular OR HbA1c) (361 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: semaglutide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: semaglutide[ti] AND (chronic kidney disease OR "knee osteoarthritis") AND randomized controlled trial[pt] (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: semaglutide[tiab] AND (depress*[ti] OR suicid*[ti] OR "psychiatric"[ti] OR Alzheimer*[ti] OR cognit*[ti]) (159 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: semaglutide[tiab] AND (blood pressure[ti] OR lipid*[ti] OR cholesterol[ti] OR "visceral"[ti] OR "waist"[ti] OR "body composition"[ti]) (112 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 23PubMed search: semaglutide[tiab] AND (rheumatoid[tiab] OR "psoriatic"[tiab] OR "inflammation"[ti] OR "C-reactive"[ti]) (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 24PubMed search: semaglutide[ti] AND ("knee osteoarthritis" OR "osteoarthritis" OR "obesity-related") AND (pain OR knee) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 25PubMed search: semaglutide[tiab] AND (Alzheimer*[tiab] OR evoke[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 26WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 27Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 28Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026
- 29A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.Expert opinion on pharmacotherapy · 2024PMID 38629387Accessed 2 Oct 2026
- 30The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy.Scientific reports · 2024PMID 39424950Accessed 2 Oct 2026
- 31ema.europa.eu pageEuropean Medicines Agency · 2026ema.europa.euAccessed 2 Oct 2026
Found an error? Report a correction.